loading

Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten

pulisher
05:59 AM

Ultragenyx Pharmaceutical (NASDAQ:RARE) Upgraded to "Strong-Buy" at Truist Financial - MarketBeat

05:59 AM
pulisher
Mar 25, 2026

Ultragenyx Pharmaceutical Stock Hits Day Low of $18.29 Amid Price Pressure - Markets Mojo

Mar 25, 2026
pulisher
Mar 25, 2026

Ultragenyx Pharmaceutical Hits Day Low at $19.86 Amid Price Pressure - Markets Mojo

Mar 25, 2026
pulisher
Mar 25, 2026

Ultragenyx Pharmaceutical Hits 52-Week Low at $18.29 Amidst Declining Performance - Markets Mojo

Mar 25, 2026
pulisher
Mar 25, 2026

Lost Money on Ultragenyx Pharmaceutical Inc.(RARE)? Join Class A - GuruFocus

Mar 25, 2026
pulisher
Mar 25, 2026

Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors - GlobeNewswire

Mar 25, 2026
pulisher
Mar 25, 2026

Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - GlobeNewswire Inc.

Mar 25, 2026
pulisher
Mar 25, 2026

RARE Investor Alert: Ultragenyx Pharmaceutical Inc. Stockholders with Large Losses Should Contact Ro - PharmiWeb.com

Mar 25, 2026
pulisher
Mar 25, 2026

Bragar Eagel & Squire, P.C. Reminds Ultragenyx (NASDAQ: - GlobeNewswire

Mar 25, 2026
pulisher
Mar 25, 2026

RARE Investor Alert: Ultragenyx Pharmaceutical Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit - The AI Journal

Mar 25, 2026
pulisher
Mar 25, 2026

Ultragenyx Nears Key Inflection Point With Completed Phase 3 Gene Therapy Study in GSDIa - TipRanks

Mar 25, 2026
pulisher
Mar 25, 2026

Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.

Mar 25, 2026
pulisher
Mar 25, 2026

Lost Money on Ultragenyx Pharmaceutical Inc.(RARE)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - PR Newswire

Mar 25, 2026
pulisher
Mar 25, 2026

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Q4 2025 earnings call transcript - MSN

Mar 25, 2026
pulisher
Mar 25, 2026

Momentum Shift: Will Ultragenyx Pharmaceutical Inc outperform tech stocksGold Moves & Free Community Supported Trade Ideas - baoquankhu1.vn

Mar 25, 2026
pulisher
Mar 25, 2026

Why Ultragenyx (RARE) Is Down 14.4% After Positive Phase 3 DTX301 Gene Therapy Results - simplywall.st

Mar 25, 2026
pulisher
Mar 24, 2026

Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 - GlobeNewswire

Mar 24, 2026
pulisher
Mar 24, 2026

Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - GlobeNewswire Inc.

Mar 24, 2026
pulisher
Mar 24, 2026

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines – RARE - ChartMill

Mar 24, 2026
pulisher
Mar 24, 2026

Goldman Sachs Downgrades Ultragenyx (RARE), Slashes Price Target by 59% | RARE Stock News - GuruFocus

Mar 24, 2026
pulisher
Mar 24, 2026

Goldman Sachs downgrades Ultragenyx Pharma stock rating to neutral By Investing.com - Investing.com India

Mar 24, 2026
pulisher
Mar 24, 2026

RARE SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - ChartMill

Mar 24, 2026
pulisher
Mar 24, 2026

Goldman Sachs Downgrades Ultragenyx (RARE) Following Trial Setba - GuruFocus

Mar 24, 2026
pulisher
Mar 24, 2026

Ultragenyx Pharmaceutical (NASDAQ:RARE) Sets New 1-Year Low After Analyst Downgrade - MarketBeat

Mar 24, 2026
pulisher
Mar 24, 2026

Ultragenyx downgraded to neutral at Goldman Sachs on setrusumab data - Seeking Alpha

Mar 24, 2026
pulisher
Mar 24, 2026

Ultragenyx stock hits 52-week low at 18.36 USD - Investing.com

Mar 24, 2026
pulisher
Mar 24, 2026

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Rating Lowered by The Goldman Sachs Group - MarketBeat

Mar 24, 2026
pulisher
Mar 24, 2026

Portnoy Law Firm Announces Class Action on Behalf of Ultragenyx Pharmaceutical, Inc. Investors - GlobeNewswire

Mar 24, 2026
pulisher
Mar 24, 2026

Holzer & Holzer, LLC Reminds Investors of April 6, 2026 Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against BlackRock TCP Capital Corp. (TCPC), Mereo BioPharma Group plc (MREO), POMDOCTOR LIMITED (POM), and Ultragenyx Phar - GlobeNewswire

Mar 24, 2026
pulisher
Mar 24, 2026

Goldman Sachs Downgrades Ultragenyx Pharmaceutical to Neutral From Buy, Adjusts PT to $25 From $61 - marketscreener.com

Mar 24, 2026
pulisher
Mar 24, 2026

Goldman Sachs downgrades Ultragenyx Pharma stock rating to neutral - Investing.com UK

Mar 24, 2026
pulisher
Mar 24, 2026

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investor Alert: Deadline in Lawsuit on April 6, 2026 - openPR.com

Mar 24, 2026
pulisher
Mar 23, 2026

INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) - GlobeNewswire

Mar 23, 2026
pulisher
Mar 23, 2026

RARE Investors Have Opportunity to Lead Ultragenyx - GlobeNewswire

Mar 23, 2026
pulisher
Mar 23, 2026

RARE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - Sahm

Mar 23, 2026
pulisher
Mar 22, 2026

WOODSTOCK CORP's Ultragenyx Pharmaceutical Inc(RARE) Holding History - GuruFocus

Mar 22, 2026
pulisher
Mar 22, 2026

Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx - GlobeNewswire

Mar 22, 2026
pulisher
Mar 22, 2026

2026-03-22 | RARE SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ultragenyx Pharmaceutical Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:RARE | Press Release - Stockhouse

Mar 22, 2026
pulisher
Mar 21, 2026

Is It Time To Reconsider Ultragenyx Pharmaceutical (RARE) After A 47% One-Year Share Price Fall - Sahm

Mar 21, 2026
pulisher
Mar 21, 2026

RARE DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Ultragenyx Pharmaceutical ... - Caledonian Record

Mar 21, 2026
pulisher
Mar 21, 2026

RARE DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.

Mar 21, 2026
pulisher
Mar 20, 2026

How Ultragenyx Pharmaceutical Inc. (RARE) Affects Rotational Strategy Timing - Stock Traders Daily

Mar 20, 2026
pulisher
Mar 20, 2026

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Mar 20, 2026
pulisher
Mar 20, 2026

A Look At Ultragenyx Pharmaceutical’s Valuation After Recent Share Price Weakness - Yahoo Finance

Mar 20, 2026
pulisher
Mar 20, 2026

Mucopolysaccharidosis Treatment Market to Reach US$6.76 - openPR.com

Mar 20, 2026
pulisher
Mar 20, 2026

INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action LawsuitRGRD Law - Lelezard

Mar 20, 2026
pulisher
Mar 20, 2026

RARE Stock Price, Quote & Chart | ULTRAGENYX PHARMACEUTICAL IN (NASDAQ:RARE) - ChartMill

Mar 20, 2026
pulisher
Mar 19, 2026

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit - ChartMill

Mar 19, 2026
pulisher
Mar 19, 2026

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming DeadlinesRARE - PR Newswire

Mar 19, 2026
pulisher
Mar 18, 2026

RARE DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. ... - Caledonian Record

Mar 18, 2026
pulisher
Mar 18, 2026

RARE DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, - GlobeNewswire

Mar 18, 2026
pulisher
Mar 18, 2026

RARE CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) ... - Bluefield Daily Telegraph

Mar 18, 2026
pulisher
Mar 18, 2026

LEVI & KORSINSKY, LLP: FRAUD-ON-THE-MARKET DOCTRINE UNDERPINS ULTRAGENYX PHARMACEUTICAL SECURITIES CLASS ACTION (2026-03-18) - Seeking Alpha

Mar 18, 2026
pulisher
Mar 17, 2026

INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. Investors - GlobeNewswire

Mar 17, 2026
pulisher
Mar 17, 2026

RARE Shareholder Alert: Ultragenyx Pharmaceutical Inc. Securitie - GuruFocus

Mar 17, 2026
pulisher
Mar 17, 2026

DTX301 Gene Therapy Lowers Ammonia Levels in Ornithine Transcarbamylase Deficiency at 36 Weeks - Neurology Live

Mar 17, 2026
$26.98
price down icon 0.99%
$47.05
price up icon 3.03%
$52.97
price up icon 3.11%
$88.06
price down icon 0.83%
ONC ONC
$272.99
price down icon 1.11%
$146.63
price up icon 6.51%
Kapitalisierung:     |  Volumen (24h):